Wedbush analyst David Nierengargten said he is optimistic that vosaroxin will meet its goals in the new trial. He kept an Outperform rating on Sunesis shares and raised his price target to $10 a share.
RBC Capital believes that Phase III data for vosaroxin could surpass expectations. The firm thinks the company has a good chance of signing a partnership deal and they maintain an Outperform rating on their stock.
This review establishes an opinion of: MARKET OUTPERFORM price target $20
Investors will probably agree with this review using their due diligence/fact checking.